Details for New Drug Application (NDA): 022184
✉ Email this page to a colleague
NDA 022184 describes LUMIGAN, which is a drug marketed by Abbvie and is included in two NDAs. It is available from one supplier. There are twelve patents protecting this drug and two Paragraph IV challenges. Additional details are available on the LUMIGAN profile page.
The generic ingredient in LUMIGAN is bimatoprost. There are twelve drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the bimatoprost profile page.
The generic ingredient in LUMIGAN is bimatoprost. There are twelve drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the bimatoprost profile page.
Summary for 022184
| Tradename: | LUMIGAN |
| Applicant: | Abbvie |
| Ingredient: | bimatoprost |
| Patents: | 12 |
Suppliers and Packaging for NDA: 022184
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| LUMIGAN | bimatoprost | SOLUTION/DROPS;OPHTHALMIC | 022184 | NDA | Allergan, Inc. | 0023-3205 | 0023-3205-02 | 1 BOTTLE, DROPPER in 1 CARTON (0023-3205-02) / 2.5 mL in 1 BOTTLE, DROPPER |
| LUMIGAN | bimatoprost | SOLUTION/DROPS;OPHTHALMIC | 022184 | NDA | Allergan, Inc. | 0023-3205 | 0023-3205-03 | 1 BOTTLE, DROPPER in 1 CARTON (0023-3205-03) / 2.5 mL in 1 BOTTLE, DROPPER |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION/DROPS;OPHTHALMIC | Strength | 0.01% | ||||
| Approval Date: | Aug 31, 2010 | TE: | AB | RLD: | Yes | ||||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Jun 13, 2027 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
| Patent: | ⤷ Get Started Free | Patent Expiration: | Mar 16, 2025 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Mar 16, 2025 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION | ||||||||
Expired US Patents for NDA 022184
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie | LUMIGAN | bimatoprost | SOLUTION/DROPS;OPHTHALMIC | 022184-001 | Aug 31, 2010 | ⤷ Get Started Free | ⤷ Get Started Free |
| Abbvie | LUMIGAN | bimatoprost | SOLUTION/DROPS;OPHTHALMIC | 022184-001 | Aug 31, 2010 | ⤷ Get Started Free | ⤷ Get Started Free |
| Abbvie | LUMIGAN | bimatoprost | SOLUTION/DROPS;OPHTHALMIC | 022184-001 | Aug 31, 2010 | ⤷ Get Started Free | ⤷ Get Started Free |
| Abbvie | LUMIGAN | bimatoprost | SOLUTION/DROPS;OPHTHALMIC | 022184-001 | Aug 31, 2010 | ⤷ Get Started Free | ⤷ Get Started Free |
| Abbvie | LUMIGAN | bimatoprost | SOLUTION/DROPS;OPHTHALMIC | 022184-001 | Aug 31, 2010 | ⤷ Get Started Free | ⤷ Get Started Free |
| Abbvie | LUMIGAN | bimatoprost | SOLUTION/DROPS;OPHTHALMIC | 022184-001 | Aug 31, 2010 | ⤷ Get Started Free | ⤷ Get Started Free |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
